Lisata Therapeutics
LSTA
27 hedge funds and large institutions have $2.62M invested in Lisata Therapeutics in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0.02% less ownership
Funds ownership: 0.52% → 0.5% (-0.02%)
7% less funds holding
Funds holding: 29 → 27 (-2)
42% less capital invested
Capital invested by funds: $4.49M → $2.62M (-$1.87M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$66K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.5K |
| 3 |
BlackRock
New York
|
+$695 |
| 4 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$139 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$87K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$69.2K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$29.2K |
| 4 |
Morgan Stanley
New York
|
-$14K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$6.95K |
LSTA Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2018, worth a combined $2.62M — down 42% from $4.49M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LSTA and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $66K. The largest seller was Ameriprise, exiting entirely with an estimated $87K sold.
- 27 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2018, down from 29 in Q3 2018.
- Funds reported $2.62M of Lisata Therapeutics stock for Q4 2018, down 42% quarter-over-quarter.
- 1 fund opened new Lisata Therapeutics positions in Q4 2018 and 3 closed out, a net change of -2 holders.
- The largest Lisata Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $66K added.
- The largest Lisata Therapeutics seller in Q4 2018 was Ameriprise, an estimated $87K sold.
Based on aggregated 13F filings for Q4 2018.